Ainos Receives IRB Approval From National Taiwan University Hospital For HIV-Oral Warts Clinical Trial, Showcasing FDA-Designated Orphan Drug VELDONA; Awaits Taiwan FDA Approval To Begin
Portfolio Pulse from Benzinga Newsdesk
Ainos has received IRB approval from National Taiwan University Hospital for a clinical trial of its FDA-designated orphan drug VELDONA, targeting HIV-related oral warts. The company is awaiting Taiwan FDA approval to commence the trial.
September 25, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ainos has received IRB approval for a clinical trial of its orphan drug VELDONA for HIV-related oral warts at National Taiwan University Hospital. The trial is pending Taiwan FDA approval.
The IRB approval is a significant step forward for Ainos, indicating progress in their clinical trial process. The designation of VELDONA as an orphan drug by the FDA adds potential value. Awaiting Taiwan FDA approval is a critical next step, but the current approval is a positive indicator.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90